Biotech Week Boston 2025

During the week of 20–25 October 2025, Aurealis Therapeutics’ CEO Juha Yrjänheikki and COO Laurent Décory traveled to Beijing, Shanghai and Hong Kong for a series of high-level meetings with key stakeholders, investors, and potential partners. The visit aimed to strengthen strategic relationships that support the development and commercialisation of Aurealis’ multi-target cell and gene therapy candidates, AUP-16 for chronic

Aurealis Therapeutics Drug Safety Officer, Matleena Piiroinen, attended  the World Drug Safety Congress Europe 2025, that took place 7–8 October in Amsterdam, The Netherlands. As Europe’s leading forum for drug safety and pharmacovigilance, the congress provides an important platform to exchange knowledge and address the most pressing challenges faced by safety professionals. At Aurealis Therapeutics, patient safety is central to